Share Price and Basic Stock Data
Last Updated: October 10, 2025, 9:43 pm
| PEG Ratio | 0.27 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Ind-Swift Laboratories Ltd, a pharmaceutical company, with a market capitalization of ₹746 Cr, has shown resilience in its sales figures. The company reported a Net Profit of ₹421 Cr, with a Profit Margin of 2.36%. Quarterly and annual sales trends indicate a steady growth trajectory, with operating profit margins reflecting efficient cost management strategies. The data suggests a positive outlook for revenue generation, supported by prudent expense control measures.
Profitability and Efficiency Metrics
With a Price-to-Earnings ratio of 33.8, Return on Equity (ROE) at 0.18%, and Return on Capital Employed (ROCE) at 0.78%, Ind-Swift Laboratories showcases moderate profitability. The Interest Coverage Ratio of 5.86x indicates a healthy ability to meet interest obligations. However, the Cash Conversion Cycle of 112 days warrants attention for potential efficiency improvements. Comparing these metrics to sector averages would provide a clearer picture of the company’s performance against industry standards.
Balance Sheet Strength and Financial Ratios
The company’s reserves stand at ₹1,104 Cr, with borrowings at ₹41 Cr, reflecting a comfortable financial position. The Price-to-Book Value ratio of 0.62x suggests the stock may be undervalued. The Interest Coverage Ratio of 5.86x indicates a robust ability to cover interest expenses. However, monitoring debt-equity ratios and liquidity positions would be essential to ensure sustainable growth and financial stability.
Shareholding Pattern and Investor Confidence
Promoters hold a significant stake at 39.49%, indicating a strong belief in the company’s potential. Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) holding at 14.90% and 0.68%, respectively, demonstrate institutional confidence. The evolving shareholding pattern influences market perception and valuation, reflecting investor sentiment and long-term confidence in the company’s performance.
Outlook, Risks, and Final Insight
Looking ahead, Ind-Swift Laboratories’ growth prospects appear promising, driven by factors such as expanding product lines and strategic partnerships. However, risks such as regulatory challenges and intense market competition could pose threats to future performance. Strengthening operational efficiency and maintaining investor trust will be critical for sustained growth. In conclusion, while the company exhibits potential for growth, mitigating risks and enhancing financial metrics will be key to unlocking its full value in the market.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Ind-Swift Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 152 Cr. | 121 | 247/84.3 | 34.6 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.98 Cr. | 2.08 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,528 Cr. | 415 | 434/192 | 102 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 31.3 Cr. | 42.2 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 29.3 Cr. | 20.0 | 29.1/17.0 | 30.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,005.64 Cr | 1,173.77 | 51.08 | 192.71 | 0.33% | 16.15% | 14.90% | 6.18 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 280.17 | 310.21 | 312.69 | 304.25 | 310.34 | 289.71 | 287.51 | 528.57 | 33.17 | 11.96 | 124.66 | 138.24 | 152.73 |
| Expenses | 227.16 | 251.45 | 258.93 | 240.58 | 250.05 | 224.02 | 235.82 | 437.36 | 42.91 | 23.76 | 131.31 | 147.44 | 149.13 |
| Operating Profit | 53.01 | 58.76 | 53.76 | 63.67 | 60.29 | 65.69 | 51.69 | 91.21 | -9.74 | -11.80 | -6.65 | -9.20 | 3.60 |
| OPM % | 18.92% | 18.94% | 17.19% | 20.93% | 19.43% | 22.67% | 17.98% | 17.26% | -29.36% | -98.66% | -5.33% | -6.66% | 2.36% |
| Other Income | 7.39 | 7.54 | 8.36 | -16.44 | 5.61 | 7.40 | 7.11 | 458.23 | 11.14 | 13.01 | 15.91 | 220.34 | 14.58 |
| Interest | 23.98 | 23.98 | 22.38 | 21.82 | 20.38 | 21.14 | 21.05 | 2.96 | 0.17 | 0.41 | 10.03 | -26.76 | 1.15 |
| Depreciation | 16.28 | 16.41 | 15.39 | 9.29 | 13.89 | 13.19 | 13.56 | 19.55 | 0.25 | 0.22 | 5.81 | 7.44 | 6.68 |
| Profit before tax | 20.14 | 25.91 | 24.35 | 16.12 | 31.63 | 38.76 | 24.19 | 526.93 | 0.98 | 0.58 | -6.58 | 230.46 | 10.35 |
| Tax % | 1.09% | 2.16% | -13.43% | 255.40% | 45.02% | 17.88% | 19.31% | 6.29% | -3.06% | 31.03% | -16.41% | 3.55% | 16.52% |
| Net Profit | 19.88 | 25.34 | 27.50 | -25.12 | 17.24 | 31.66 | 19.42 | 493.68 | 0.94 | 0.41 | -5.49 | 222.27 | 8.77 |
| EPS in Rs | 3.36 | 4.29 | 4.65 | -4.25 | 2.92 | 5.36 | 3.29 | 83.55 | 0.16 | 0.07 | -0.93 | 36.67 | 1.45 |
Last Updated: August 20, 2025, 9:05 am
Below is a detailed analysis of the quarterly data for Ind-Swift Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 152.73 Cr.. The value appears strong and on an upward trend. It has increased from 138.24 Cr. (Mar 2025) to 152.73 Cr., marking an increase of 14.49 Cr..
- For Expenses, as of Jun 2025, the value is 149.13 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 147.44 Cr. (Mar 2025) to 149.13 Cr., marking an increase of 1.69 Cr..
- For Operating Profit, as of Jun 2025, the value is 3.60 Cr.. The value appears strong and on an upward trend. It has increased from -9.20 Cr. (Mar 2025) to 3.60 Cr., marking an increase of 12.80 Cr..
- For OPM %, as of Jun 2025, the value is 2.36%. The value appears strong and on an upward trend. It has increased from -6.66% (Mar 2025) to 2.36%, marking an increase of 9.02%.
- For Other Income, as of Jun 2025, the value is 14.58 Cr.. The value appears to be declining and may need further review. It has decreased from 220.34 Cr. (Mar 2025) to 14.58 Cr., marking a decrease of 205.76 Cr..
- For Interest, as of Jun 2025, the value is 1.15 Cr.. The value appears to be increasing, which may not be favorable. It has increased from -26.76 Cr. (Mar 2025) to 1.15 Cr., marking an increase of 27.91 Cr..
- For Depreciation, as of Jun 2025, the value is 6.68 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 7.44 Cr. (Mar 2025) to 6.68 Cr., marking a decrease of 0.76 Cr..
- For Profit before tax, as of Jun 2025, the value is 10.35 Cr.. The value appears to be declining and may need further review. It has decreased from 230.46 Cr. (Mar 2025) to 10.35 Cr., marking a decrease of 220.11 Cr..
- For Tax %, as of Jun 2025, the value is 16.52%. The value appears to be increasing, which may not be favorable. It has increased from 3.55% (Mar 2025) to 16.52%, marking an increase of 12.97%.
- For Net Profit, as of Jun 2025, the value is 8.77 Cr.. The value appears to be declining and may need further review. It has decreased from 222.27 Cr. (Mar 2025) to 8.77 Cr., marking a decrease of 213.50 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.45. The value appears to be declining and may need further review. It has decreased from 36.67 (Mar 2025) to 1.45, marking a decrease of 35.22.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: March 6, 2025, 3:56 pm
| Metric | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,134 | 965 | 660 | 653 | 716 | 765 | 757 | 780 | 891 | 1,039 | 1,207 | 1,281 | 447 |
| Expenses | 1,063 | 906 | 571 | 546 | 610 | 631 | 630 | 635 | 709 | 837 | 978 | 1,029 | 407 |
| Operating Profit | 72 | 59 | 89 | 107 | 106 | 134 | 126 | 144 | 183 | 202 | 229 | 252 | 40 |
| OPM % | 6% | 6% | 13% | 16% | 15% | 18% | 17% | 19% | 21% | 19% | 19% | 20% | 9% |
| Other Income | 4 | -19 | -31 | 1 | 15 | 16 | 120 | 33 | 23 | 37 | 7 | 434 | 450 |
| Interest | 140 | 117 | 117 | 106 | 88 | 28 | 92 | 107 | 100 | 96 | 92 | 51 | -11 |
| Depreciation | 54 | 66 | 84 | 85 | 88 | 87 | 104 | 90 | 87 | 131 | 57 | 53 | 13 |
| Profit before tax | -119 | -142 | -143 | -83 | -55 | 36 | 50 | -20 | 18 | 13 | 87 | 582 | 488 |
| Tax % | -1% | -14% | -17% | -29% | -29% | 39% | 42% | 7% | 117% | 117% | 45% | 28% | |
| Net Profit | -118 | -122 | -119 | -59 | -39 | 22 | 29 | -21 | -3 | -2 | 48 | 421 | 354 |
| EPS in Rs | -30.02 | -29.79 | -29.14 | -14.33 | -8.75 | 4.85 | 6.09 | -3.59 | -0.53 | -0.36 | 8.06 | 71.24 | 59.91 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2013-2014 | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -3.39% | 2.46% | 50.42% | 33.90% | 156.41% | 31.82% | -172.41% | 85.71% | 33.33% | 2500.00% | 777.08% |
| Change in YoY Net Profit Growth (%) | 0.00% | 5.85% | 47.96% | -16.52% | 122.51% | -124.59% | -204.23% | 258.13% | -52.38% | 2466.67% | -1722.92% |
Ind-Swift Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -6% |
| 3 Years: | -19% |
| TTM: | -62% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 30% |
| 3 Years: | 205% |
| TTM: | -88% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 24% |
| 3 Years: | 20% |
| 1 Year: | -32% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 6% |
| 3 Years: | 10% |
| Last Year: | 4% |
Last Updated: September 5, 2025, 7:30 am
Balance Sheet
Last Updated: October 10, 2025, 2:15 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 41 | 42 | 42 | 45 | 46 | 48 | 60 | 60 | 60 | 60 | 67 | 69 |
| Reserves | 684 | 553 | 476 | 486 | 507 | 540 | 581 | 544 | 541 | 622 | 745 | 1,104 |
| Borrowings | 1,355 | 1,413 | 1,457 | 1,242 | 1,083 | 1,148 | 1,031 | 1,005 | 953 | 862 | 217 | 41 |
| Other Liabilities | 258 | 236 | 240 | 364 | 387 | 188 | 198 | 210 | 247 | 280 | 432 | 224 |
| Total Liabilities | 2,339 | 2,244 | 2,215 | 2,138 | 2,023 | 1,924 | 1,870 | 1,818 | 1,801 | 1,824 | 1,460 | 1,438 |
| Fixed Assets | 1,174 | 1,117 | 1,099 | 1,042 | 934 | 914 | 843 | 753 | 630 | 587 | 192 | 273 |
| CWIP | 78 | 113 | 78 | 70 | 69 | 20 | 11 | 19 | 10 | 8 | 51 | 0 |
| Investments | 17 | 18 | 18 | 18 | 18 | 19 | 17 | 36 | 29 | 30 | 112 | 213 |
| Other Assets | 1,070 | 997 | 1,020 | 1,007 | 1,002 | 972 | 998 | 1,011 | 1,131 | 1,199 | 1,106 | 952 |
| Total Assets | 2,339 | 2,244 | 2,215 | 2,138 | 2,023 | 1,924 | 1,870 | 1,818 | 1,801 | 1,824 | 1,460 | 1,438 |
Below is a detailed analysis of the balance sheet data for Ind-Swift Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 69.00 Cr.. The value appears strong and on an upward trend. It has increased from 67.00 Cr. (Mar 2024) to 69.00 Cr., marking an increase of 2.00 Cr..
- For Reserves, as of Mar 2025, the value is 1,104.00 Cr.. The value appears strong and on an upward trend. It has increased from 745.00 Cr. (Mar 2024) to 1,104.00 Cr., marking an increase of 359.00 Cr..
- For Borrowings, as of Mar 2025, the value is 41.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 217.00 Cr. (Mar 2024) to 41.00 Cr., marking a decrease of 176.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 224.00 Cr.. The value appears to be improving (decreasing). It has decreased from 432.00 Cr. (Mar 2024) to 224.00 Cr., marking a decrease of 208.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 1,438.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,460.00 Cr. (Mar 2024) to 1,438.00 Cr., marking a decrease of 22.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 273.00 Cr.. The value appears strong and on an upward trend. It has increased from 192.00 Cr. (Mar 2024) to 273.00 Cr., marking an increase of 81.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 51.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 51.00 Cr..
- For Investments, as of Mar 2025, the value is 213.00 Cr.. The value appears strong and on an upward trend. It has increased from 112.00 Cr. (Mar 2024) to 213.00 Cr., marking an increase of 101.00 Cr..
- For Other Assets, as of Mar 2025, the value is 952.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,106.00 Cr. (Mar 2024) to 952.00 Cr., marking a decrease of 154.00 Cr..
- For Total Assets, as of Mar 2025, the value is 1,438.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,460.00 Cr. (Mar 2024) to 1,438.00 Cr., marking a decrease of 22.00 Cr..
Notably, the Reserves (1,104.00 Cr.) exceed the Borrowings (41.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 72.00 | 58.00 | 88.00 | 106.00 | 105.00 | 133.00 | 125.00 | 143.00 | 182.00 | -751.00 | -633.00 | 35.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 168 | 215 | 208 | 182 | 194 | 169 | 186 | 177 | 160 | 153 | 48 | 107 |
| Inventory Days | 182 | 312 | 368 | 305 | 291 | 284 | 315 | 301 | 288 | 242 | 6 | 145 |
| Days Payable | 103 | 120 | 137 | 91 | 118 | 114 | 124 | 111 | 118 | 113 | 52 | 140 |
| Cash Conversion Cycle | 247 | 407 | 439 | 396 | 367 | 339 | 377 | 367 | 330 | 282 | 2 | 112 |
| Working Capital Days | 129 | 141 | -26 | -97 | -49 | 217 | 248 | 253 | 253 | 234 | 2 | 141 |
| ROCE % | 0% | 1% | 2% | 2% | 4% | 4% | 5% | 7% | 7% | 13% | 20% | 3% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 71.24 | 8.10 | -0.36 | -0.53 | -4.28 |
| Diluted EPS (Rs.) | 71.24 | 8.10 | -0.36 | -0.53 | -4.28 |
| Cash EPS (Rs.) | 80.35 | 17.59 | 21.55 | 14.07 | 11.52 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 157.64 | 83.36 | 67.61 | 65.66 | 69.48 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 157.64 | 114.02 | 100.47 | 100.90 | 107.12 |
| Revenue From Operations / Share (Rs.) | 216.78 | 201.87 | 173.68 | 149.04 | 130.36 |
| PBDIT / Share (Rs.) | 50.70 | 43.92 | 39.98 | 34.36 | 29.73 |
| PBIT / Share (Rs.) | 41.68 | 34.33 | 18.07 | 19.77 | 14.67 |
| PBT / Share (Rs.) | 98.46 | 14.47 | 2.10 | 3.01 | -3.31 |
| Net Profit / Share (Rs.) | 71.33 | 8.00 | -0.35 | -0.52 | -3.54 |
| NP After MI And SOA / Share (Rs.) | 71.24 | 7.96 | -0.35 | -0.52 | -3.54 |
| PBDIT Margin (%) | 23.38 | 21.75 | 23.01 | 23.05 | 22.80 |
| PBIT Margin (%) | 19.22 | 17.00 | 10.40 | 13.26 | 11.25 |
| PBT Margin (%) | 45.41 | 7.16 | 1.20 | 2.02 | -2.53 |
| Net Profit Margin (%) | 32.90 | 3.96 | -0.20 | -0.35 | -2.71 |
| NP After MI And SOA Margin (%) | 32.86 | 3.94 | -0.20 | -0.35 | -2.71 |
| Return on Networth / Equity (%) | 45.19 | 9.54 | -0.53 | -0.80 | -5.09 |
| Return on Capital Employeed (%) | 26.09 | 14.13 | 7.36 | 7.86 | 5.67 |
| Return On Assets (%) | 36.13 | 2.60 | -0.11 | -0.17 | -1.13 |
| Long Term Debt / Equity (X) | 0.01 | 1.51 | 2.10 | 2.25 | 2.14 |
| Total Debt / Equity (X) | 0.01 | 1.73 | 2.35 | 2.56 | 2.48 |
| Asset Turnover Ratio (%) | 0.85 | 0.66 | 0.54 | 0.46 | 0.39 |
| Current Ratio (X) | 2.99 | 3.14 | 3.22 | 3.00 | 2.67 |
| Quick Ratio (X) | 2.94 | 1.96 | 1.94 | 1.81 | 1.61 |
| Inventory Turnover Ratio (X) | 2.67 | 1.52 | 1.33 | 1.23 | 1.19 |
| Interest Coverage Ratio (X) | 5.86 | 2.85 | 2.50 | 2.05 | 1.65 |
| Interest Coverage Ratio (Post Tax) (X) | 1.68 | 1.81 | 0.97 | 0.96 | 0.80 |
| Enterprise Value (Cr.) | 165.50 | 1173.71 | 1328.01 | 1424.06 | 1150.03 |
| EV / Net Operating Revenue (X) | 0.12 | 0.97 | 1.28 | 1.60 | 1.48 |
| EV / EBITDA (X) | 0.55 | 4.47 | 5.55 | 6.93 | 6.47 |
| MarketCap / Net Operating Revenue (X) | 0.45 | 0.27 | 0.38 | 0.48 | 0.16 |
| Price / BV (X) | 0.62 | 0.66 | 0.98 | 1.10 | 0.31 |
| Price / Net Operating Revenue (X) | 0.45 | 0.27 | 0.38 | 0.48 | 0.16 |
| EarningsYield | 0.72 | 0.14 | -0.01 | -0.01 | -0.16 |
After reviewing the key financial ratios for Ind-Swift Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 71.24. This value is within the healthy range. It has increased from 8.10 (Mar 23) to 71.24, marking an increase of 63.14.
- For Diluted EPS (Rs.), as of Mar 24, the value is 71.24. This value is within the healthy range. It has increased from 8.10 (Mar 23) to 71.24, marking an increase of 63.14.
- For Cash EPS (Rs.), as of Mar 24, the value is 80.35. This value is within the healthy range. It has increased from 17.59 (Mar 23) to 80.35, marking an increase of 62.76.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 157.64. It has increased from 83.36 (Mar 23) to 157.64, marking an increase of 74.28.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 157.64. It has increased from 114.02 (Mar 23) to 157.64, marking an increase of 43.62.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 216.78. It has increased from 201.87 (Mar 23) to 216.78, marking an increase of 14.91.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 50.70. This value is within the healthy range. It has increased from 43.92 (Mar 23) to 50.70, marking an increase of 6.78.
- For PBIT / Share (Rs.), as of Mar 24, the value is 41.68. This value is within the healthy range. It has increased from 34.33 (Mar 23) to 41.68, marking an increase of 7.35.
- For PBT / Share (Rs.), as of Mar 24, the value is 98.46. This value is within the healthy range. It has increased from 14.47 (Mar 23) to 98.46, marking an increase of 83.99.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 71.33. This value is within the healthy range. It has increased from 8.00 (Mar 23) to 71.33, marking an increase of 63.33.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 71.24. This value is within the healthy range. It has increased from 7.96 (Mar 23) to 71.24, marking an increase of 63.28.
- For PBDIT Margin (%), as of Mar 24, the value is 23.38. This value is within the healthy range. It has increased from 21.75 (Mar 23) to 23.38, marking an increase of 1.63.
- For PBIT Margin (%), as of Mar 24, the value is 19.22. This value is within the healthy range. It has increased from 17.00 (Mar 23) to 19.22, marking an increase of 2.22.
- For PBT Margin (%), as of Mar 24, the value is 45.41. This value is within the healthy range. It has increased from 7.16 (Mar 23) to 45.41, marking an increase of 38.25.
- For Net Profit Margin (%), as of Mar 24, the value is 32.90. This value exceeds the healthy maximum of 10. It has increased from 3.96 (Mar 23) to 32.90, marking an increase of 28.94.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is 32.86. This value exceeds the healthy maximum of 20. It has increased from 3.94 (Mar 23) to 32.86, marking an increase of 28.92.
- For Return on Networth / Equity (%), as of Mar 24, the value is 45.19. This value is within the healthy range. It has increased from 9.54 (Mar 23) to 45.19, marking an increase of 35.65.
- For Return on Capital Employeed (%), as of Mar 24, the value is 26.09. This value is within the healthy range. It has increased from 14.13 (Mar 23) to 26.09, marking an increase of 11.96.
- For Return On Assets (%), as of Mar 24, the value is 36.13. This value is within the healthy range. It has increased from 2.60 (Mar 23) to 36.13, marking an increase of 33.53.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.01. This value is below the healthy minimum of 0.2. It has decreased from 1.51 (Mar 23) to 0.01, marking a decrease of 1.50.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.01. This value is within the healthy range. It has decreased from 1.73 (Mar 23) to 0.01, marking a decrease of 1.72.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.85. It has increased from 0.66 (Mar 23) to 0.85, marking an increase of 0.19.
- For Current Ratio (X), as of Mar 24, the value is 2.99. This value is within the healthy range. It has decreased from 3.14 (Mar 23) to 2.99, marking a decrease of 0.15.
- For Quick Ratio (X), as of Mar 24, the value is 2.94. This value exceeds the healthy maximum of 2. It has increased from 1.96 (Mar 23) to 2.94, marking an increase of 0.98.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 2.67. This value is below the healthy minimum of 4. It has increased from 1.52 (Mar 23) to 2.67, marking an increase of 1.15.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 5.86. This value is within the healthy range. It has increased from 2.85 (Mar 23) to 5.86, marking an increase of 3.01.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 1.68. This value is below the healthy minimum of 3. It has decreased from 1.81 (Mar 23) to 1.68, marking a decrease of 0.13.
- For Enterprise Value (Cr.), as of Mar 24, the value is 165.50. It has decreased from 1,173.71 (Mar 23) to 165.50, marking a decrease of 1,008.21.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 0.12. This value is below the healthy minimum of 1. It has decreased from 0.97 (Mar 23) to 0.12, marking a decrease of 0.85.
- For EV / EBITDA (X), as of Mar 24, the value is 0.55. This value is below the healthy minimum of 5. It has decreased from 4.47 (Mar 23) to 0.55, marking a decrease of 3.92.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 0.45. This value is below the healthy minimum of 1. It has increased from 0.27 (Mar 23) to 0.45, marking an increase of 0.18.
- For Price / BV (X), as of Mar 24, the value is 0.62. This value is below the healthy minimum of 1. It has decreased from 0.66 (Mar 23) to 0.62, marking a decrease of 0.04.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 0.45. This value is below the healthy minimum of 1. It has increased from 0.27 (Mar 23) to 0.45, marking an increase of 0.18.
- For EarningsYield, as of Mar 24, the value is 0.72. This value is below the healthy minimum of 5. It has increased from 0.14 (Mar 23) to 0.72, marking an increase of 0.58.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ind-Swift Laboratories Ltd:
- Net Profit Margin: 32.9%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 26.09% (Industry Average ROCE: 16.02%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 45.19% (Industry Average ROE: 14.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.68
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.94
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 34.8 (Industry average Stock P/E: 42.29)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 32.9%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | SCO 850, Shivalik Enclave, Chandigarh Chandigarh 160101 | investor@indswiftlabs.com http://www.indswiftlabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Navrattan Munjal | Chairman & Managing Director |
| Mr. Himanshu Jain | Joint Managing Director |
| Mr. Rishav Mehta | Executive Director |
| Mr. Sahil Munjal | Executive Director |
| Mr. S P Sharma | Independent Director |
| Mr. Param Bir Singh | Independent Director |
| Dr. Ashwani Kumar Vig | Independent Director |
| Mr. Rajinder Kumar Gupta | Independent Director |
| Ms. Neerja Chathley | Independent Woman Director |
FAQ
What is the intrinsic value of Ind-Swift Laboratories Ltd?
Ind-Swift Laboratories Ltd's intrinsic value (as of 10 October 2025) is 9.92 which is 90.55% lower the current market price of 105.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹769 Cr. market cap, FY2025-2026 high/low of 134/67.2, reserves of ₹1,104 Cr, and liabilities of 1,438 Cr.
What is the Market Cap of Ind-Swift Laboratories Ltd?
The Market Cap of Ind-Swift Laboratories Ltd is 769 Cr..
What is the current Stock Price of Ind-Swift Laboratories Ltd as on 10 October 2025?
The current stock price of Ind-Swift Laboratories Ltd as on 10 October 2025 is 105.
What is the High / Low of Ind-Swift Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ind-Swift Laboratories Ltd stocks is 134/67.2.
What is the Stock P/E of Ind-Swift Laboratories Ltd?
The Stock P/E of Ind-Swift Laboratories Ltd is 34.8.
What is the Book Value of Ind-Swift Laboratories Ltd?
The Book Value of Ind-Swift Laboratories Ltd is 194.
What is the Dividend Yield of Ind-Swift Laboratories Ltd?
The Dividend Yield of Ind-Swift Laboratories Ltd is 0.00 %.
What is the ROCE of Ind-Swift Laboratories Ltd?
The ROCE of Ind-Swift Laboratories Ltd is 0.78 %.
What is the ROE of Ind-Swift Laboratories Ltd?
The ROE of Ind-Swift Laboratories Ltd is 0.18 %.
What is the Face Value of Ind-Swift Laboratories Ltd?
The Face Value of Ind-Swift Laboratories Ltd is 10.0.